News About: Goverment
Sprycel price remains controversial
The dispute over the insurance price of Sprycel, anticancer, is expected to be going on since a group of leukemia patients demanded more reasonable price.
"We don't think there are any acceptable reasons for BMS K...
767 expensive insurance medicines released
The Health Insurance Review Agency has recently announced a list of 767 expensive medicines in the second quarter of this year, up 26 items compared with 741 items in the first quarter.
The list includes MSD's Cozz...
Physical activity and exercise key to successful weight loss, KFDA says
Despite the fact that the use of pharmacotherapy produced a more rapid initial weight loss, physical activity and exercise are key to successful weight loss and weight loss maintenance, according to the Korea Food and...
Insurance price of Sprycel to be determined at end of March
The Ministry of Health, Welfare and Family Affairs said the insurance price of Sprycel would be finally determined at the end of this month as the National Health Insurance Corporation and BMS Korea failed to reach an...
Kim Soung-yee takes offices
Minister of Health, Welfare and Family Affairs Kim Soung-yee took office on March 13, despite objections from opposition parties for his alleged illicit real estate trading and misappropriation of public funds.
Pre...
Medicines with change in dosage form to be included in incentive list
Newly salt-modified drugs and medicines with change in dosage form will get more incentive in the process of assessing "high quality, cost-effective" drugs, according to the Ministry of Health, Welfare and Family Affa...
Four proposals planned over price of Sprycel
The insurance price coordination committee will propose four proposals to BMS Korea in the process of determining the insurance price of Spraycel, anticancer medicine, according to the Ministry of Health, Welfare and ...
Screening period to be shortened over salt-modified medicines
The Health Insurance Review & Assessment Service said it will revise rules to shorten the screening period of salt- or dosage form-modified drugs to a period of 60-90 days, down from the current 150 days, in a move ai...
Sprycel to undergo pricing readjustments
The government plans to review the pricing feasibility of BMS's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases, at the meeting of an insurance price coordination committee to be first held during ...
Positive list system baffles drug makers
Concerns are mounting among drug makers over the so-called positive list system that may affect their export drive of generic drugs, although they are spending huge investments to construct or upgrade their GMP (good ...
